Results 1 to 10 of about 19,474 (223)
Systematic Targeting of GD2‐Positive Neuroblastoma Tumors With a Photooncolytic Phage Nanovector Platform [PDF]
Advanced ScienceDisialoganglioside‐GD2 is a key molecular target for Neuroblastoma (NB) immunotherapy based on the employment of GD2‐targeting antibodies. However, about 50% of treated patients can experience tumor relapse due to limited immune‐mediated cytotoxicity and
Suleman Khan Zadran +25 more
doaj +3 more sources
RNA Sequencing-Based Identification of Ganglioside GD2-Positive Cancer Phenotype
Biomedicines, 2020 The tumor-associated ganglioside GD2 represents an attractive target for cancer immunotherapy. GD2-positive tumors are more responsive to such targeted therapy, and new methods are needed for the screening of GD2 molecular tumor phenotypes. In this work,
Roman Kholodenko +2 more
exaly +4 more sources
Molecules, 2019 Antigen-binding fragments of antibodies specific to the tumor-associated ganglioside GD2 are well poised to play a substantial role in modern GD2-targeted cancer therapies, however, rapid elimination from the body and reduced affinity compared to full ...
Roman Kholodenko +2 more
exaly +4 more sources
Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas
Frontiers in Immunology, 2023 BackgroundDiffuse intrinsic pontine gliomas (DIPGs) are rare and fatal pediatric brainstem gliomas with no cure. Chimeric antigen receptor (CAR)-engineered natural killer (NK) cells have been proven effective in treating glioblastoma (GBM) in preclinical
Pengcheng Zuo +11 more
doaj +2 more sources
Biology of GD2 ganglioside: implications for cancer immunotherapy
Frontiers in Pharmacology, 2023 Part of the broader glycosphingolipid family, gangliosides are composed of a ceramide bound to a sialic acid-containing glycan chain, and locate at the plasma membrane.
Pierre Machy +2 more
doaj +2 more sources
Anti-PD-L1 scFv-secreting fifth-generation GD2-CAR T cells enhance antitumor function against GD2-low retinoblastoma [PDF]
Molecular Therapy: Nucleic AcidsRetinoblastoma (RB) is an aggressive pediatric intraocular malignancy in which chemoresistant or relapsed disease often requires enucleation, leading to vision loss.
Pornpimon Yuti +8 more
doaj +2 more sources
Translational Oncology, 2021 A novel disialoganglioside 2 (GD2)-specific chimeric antigen receptor (CAR)-modified T cell therapy against retinoblastoma (RB) were generated. GD2-CAR consists of a single-chain variable fragment (scFv) derived from a monoclonal antibody, hu3F8, that is
Pa-Thai Yenchitsomanus +2 more
exaly +3 more sources
Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma
Biomolecules, 2022 Neuroblastoma is one of the few childhood cancers that carries a tumor-specific antigen in the form of a glycolipid antigen known as GD2. It has restricted expression in normal tissue, such as peripheral afferent nerves.
Godfrey Chi Fung Chan
exaly +3 more sources
A novel therapeutic strategy for osteosarcoma using anti-GD2 ADC and EZH2 inhibitor
Biomarker ResearchOsteosarcoma is the commonest malignant bone tumour in children, with a poor prognosis due to limited treatment options. Antibody–drug conjugates (ADCs) offer targeted therapeutic potential but are limited by the low expression of specific antigens like ...
Jing Shan +14 more
doaj +2 more sources
Umbilical cord blood natural killer cells improve anti-GD2 antibody efficacy in neuroblastoma: from mouse to human [PDF]
OncoImmunologyDespite advances in anti-disialoganglioside (GD2) immunotherapy, high-risk neuroblastoma (NB) remains a clinical challenge. Natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity is a potent mechanism of action of anti-GD2 antibody ...
Mengjia Song +16 more
doaj +2 more sources